leisure time -WSS

leisure time

author：knowledge 2025-08-31 08:28:27 - browse：559

prostate cancer cells — Prostate cancer cells seen under the microscope. NIH

Prostate cancer tends to be the tortoise of tumors, growing and spreading slowly. When cancerous cells escape the golf ball-sized prostate, they can lodge in various places throughout the body. New research shows that where these cells go can affect how long a man survives.

When prostate cancer spreads, or metastasizes, about three-quarters of the time it takes up residence in the bones. Less common locations are the lungs, liver, and lymph nodes.

An international team of researchers pooled information from nine clinical trials to estimate the average survival times for men with prostate cancer that had spread to four different tissues. Metastasis to the lymph nodes was linked to the longest survival; metastasis to the liver led to the shortest.

“This important study confirms that one size does not fit all when it comes to metastatic prostate cancer,” said Dr. Marc Garnick, a prostate cancer specialist at Beth Israel Deaconess Medical Center in Boston.

The new study, led by Susan Halabi, a professor of biostatistics at Duke University School of Medicine, suggests that prostate cancer that skips the bones and spreads to the liver and lungs may represent a different disease than prostate cancer that invades bones or lymph nodes. The results were published Monday in the Journal of Clinical Oncology.

Median survival for metastatic prostate cancer is affected by metastasis site. Mark Dubowski for Duke Health

“A better understanding of how metastatic prostate cancer behaves in different locations is letting us tailor diagnostic approaches and treatments that we hope will improve outcomes,” Garnick said.

Previous article： The high cost of giving birth even with insurance
Next article： How generative AI ratchets up security threats for health systems

leisure time

focus

WSS

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Illumina board agrees to spin off Grail, as divestment plans proceed

Health Care Service Corp to buy Cigna Medicare Advantage plans

Finland to offer bird flu vaccine to select groups of people, a possible global first

explore

leisure time

hotspot

Hollywood unions extend contract negotiations for actors

Structure Therapeutics oral GLP

23andMe had bad news about my health. I wish a person had delivered it

Congress needs to close a vaccine

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Merck, Johnson & Johnson CEOs will testify on high drug prices

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: The latest on Novavax, Merck, Bluebird

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Investment in vaccine development is lagging, report finds

hotspot

FTC loses bid to block Novant's North Carolina hospital merger

Zyn nicotine pouches become unlikely player in latest culture war

CMS got Medicare Advantage quality rating wrong, judge rules

Health Care Service Corp to buy Cigna Medicare Advantage plans

How CO2 helps viruses stay alive longer in the air

Eli Lilly’s Zepbound improved liver scarring in mid

leisure time

focus

explore

entertainment